Equity Profile

CELC

Celcuity Inc.

Health CareBiotechnology$4.3B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Although specific revenue estimates are not available, any growth in revenue would signal strong demand for Celcuity's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer. With a market cap of $6 billion, it operates in the healthcare sector, aiming to improve patient outcomes through its unique approach to drug discovery and development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

In Q1 2026, Celcuity reported an EPS of -$0.86, which was better than the expected -$1.07, resulting in a positive stock reaction of 8.23% the following day. The company has consistently surprised analysts with better-than-expected EPS in recent quarters.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Celcuity's upcoming earnings report are mixed, given the lack of analyst estimates and management guidance. Investors are keen to see if the company can maintain its trend of positive EPS surprises.

Bull Case

If Celcuity continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could lead to increased investor confidence and a strong stock performance.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its clinical trials, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch for any delays or advancements, as these can significantly impact the company's future prospects and stock performance.

How does management view the competitive landscape in oncology treatments?

Understanding Celcuity's position relative to competitors will help investors gauge its market potential and strategic direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Celcuity's clinical trials to yield positive results, given the company's recent track record of EPS surprises.

Supporting Evidence

Celcuity has consistently beaten EPS estimates in the past quarters, suggesting stronger underlying performance than anticipated.

The options market is pricing a significant move, indicating that investors expect volatility, which could be driven by positive news.

Insider activity has been routine, suggesting confidence in the company's direction despite the lack of recent open-market transactions.

Key Risk

If clinical trial results exceed expectations, it could lead to a significant revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Celcuity's ability to deliver on its clinical development promises and maintain its positive earnings surprise trend.

Bull Confirmed If

A positive update on clinical trial results or timelines could confirm the bull case.

Bear Confirmed If

Any delays or negative results from clinical trials would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move of approximately 12.5% in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations and raises guidance, history suggests the stock could see an average one-day move of +3.4%, confirming bullish sentiment.

In-Line / Cautious

An in-line report with cautious commentary may lead to a muted response, as investors reassess their expectations.

Miss

If the company misses expectations, history indicates a potential average decline of -2.44%, which could trigger a sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials and any new data.
2Management's commentary on competitive positioning in the oncology market.
3Any changes to the timeline for product launches or regulatory approvals.
4Insights into partnerships or collaborations that could enhance growth prospects.
5Guidance on future earnings expectations or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ePlus inc.

Company Snapshot

Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Although specific revenue estimates are not available, any growth in revenue would signal strong demand for Celcuity's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CELC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+10.76%

Avg Stock Reaction

+1.94%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Celcuity continues its trend of beating EPS estimates and provides positive updates on clinical trials, it could lead to increased investor confidence and a strong stock performance.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its clinical trials, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

The market will closely watch for any delays or advancements, as these can significantly impact the company's future prospects and stock performance.

How does management view the competitive landscape in oncology treatments?

Understanding Celcuity's position relative to competitors will help investors gauge its market potential and strategic direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Celcuity's clinical trials to yield positive results, given the company's recent track record of EPS surprises.

Supporting Evidence

Celcuity has consistently beaten EPS estimates in the past quarters, suggesting stronger underlying performance than anticipated.

The options market is pricing a significant move, indicating that investors expect volatility, which could be driven by positive news.

Insider activity has been routine, suggesting confidence in the company's direction despite the lack of recent open-market transactions.

Key Risk

If clinical trial results exceed expectations, it could lead to a significant revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Celcuity's ability to deliver on its clinical development promises and maintain its positive earnings surprise trend.

Bull Confirmed If

A positive update on clinical trial results or timelines could confirm the bull case.

Bear Confirmed If

Any delays or negative results from clinical trials would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.47%

Historical Avg

±4.1%

Pricing rich

The options market is pricing in a significant move of approximately 12.5% in either direction, indicating heightened uncertainty ahead of the earnings report.

Options are pricing ±12.5% while CELC has averaged ±4.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

73.5%

Calls (79K)P/C Ratio: 0.54Puts (54K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celcuity beats expectations and raises guidance, history suggests the stock could see an average one-day move of +3.4%, confirming bullish sentiment.

In-Line / Cautious

An in-line report with cautious commentary may lead to a muted response, as investors reassess their expectations.

Miss

If the company misses expectations, history indicates a potential average decline of -2.44%, which could trigger a sell-off.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials and any new data.
2Management's commentary on competitive positioning in the oncology market.
3Any changes to the timeline for product launches or regulatory approvals.
4Insights into partnerships or collaborations that could enhance growth prospects.
5Guidance on future earnings expectations or strategic initiatives.